Table 2 Study characteristics.
Study | Type of SGLT-2 (dose, mg) | Number of participants | Median follow-up, years | Age, years | Women (%) | ACEI- ARB at baseline (%) | uACR > 30 mg/g | Diabetes (%) | Baseline eGFR < 60* | Established CV disease | History of heart failure |
|---|---|---|---|---|---|---|---|---|---|---|---|
EMPA-REG outcome | Empagliflozin (10 and 25) | 7020 | 3.1 | 63 (8.7) | 28.5 | 5666 (80.7%) | 2782 (40.0) | 7020 (100) | 1819 (25.9) | 7020 (100) | 706 (10.1) |
CANVAS | Canagliflozin (100 and 300) | 10,142 | 2.4 | 63.3 (8.3) | 35.8 | 8116 (80%) | 3026 (30.0) | 10,142 (100) | 2039 (20.1) | 6656 (65.6) | 1461 (14.4) |
DECLARE-TIMI 58 | Dapagliflozin (10) | 17,160 | 4.2 | 63.9 (6.8) | 37.4 | 13,950 (81.3%) | 5199 (30.3) | 17,160 (100) | 1265 (7.4) | 6974 (40.6) | 1724 (10.0) |
CREDENCE | Canagliflozin (100) | 4401 | 2.6 | 63.0 (9.2) | 33.9 | 4395 (99.9%) | 4401 (100) | 4401 (100) | 2592 (58.9) | 2223 (50.5) | 652 (14.8) |
DAPA-CKD | Dapagliflozin (10) | 4304 | 2.4 | 61.85 (12.1) | 33.1 | 4224 (98.1%) | 4304 (100) | 2906 (67.5) | 3850 (89.5) | 1610 (37.4) | 468 (10.9) |
DAPA-HF | Dapagliflozin (10) | 4744 | 1.5 | 66.3 (10.9) | 23.4 | 4460 (94%) | NA | 1983 (41.8) | 1926 (40.6) | 4744 (100) | 4744 (100) |
VERTIS-CV | Ertugliflozin (5 and 15) | 8246 | 3.5 | 64.4 (8.05) | 29.9 | 6686 (81.1%) | 3247 (39.4) | 8246 (100) | 1807 (21.9) | 8238 (99.9) | 1958 (23.7) |
SCORED | Sotagliflozin (200 to 400) | 10,584 | 1.33 | 69 (NA) | 44.9 | 9229 (87.2%) | 6875 (65.0) | 10,584 (100) | 10,584 (100) | NA | 3283 (31.0) |
EMPEROR-REDUCED | Empagliflozin (10) | 3730 | 1.33 | 66.85 (11) | 23.9 | 3327 (89.2%) | 1632 (43.8) | 1856 (49.8) | 1799 (48.2) | 3730 (100) | 3730 (100) |
EMPEROR-PRESERVED | Empagliflozin (10) | 5988 | 2.2 | 71.9 (9.6) | 44.7 | 4832 (80.7%) | NA | 2938 (49.1) | 2988 (49.9) | 5988 (100) | 5988 (100) |
DELIVER | Dapagliflozin (10) | 6263 | 2.3 | 71.7 (9.6) | 43.9 | 2272 (36.3%) | NA | 2806 (44.8%) | 3070 (49.0) | 6263 (100) | 6263 (100) |
EMPA-KIDNEY | Empagliflozin (10) | 6609 | 2.0 | 63.9 (13.9) | 33.2 | 5628 (85.2%) | 5281 (79.9%) | 3040 (46.0%) | 5210 (78.8)* | 1765 (26.7) | NA |
